Spotlight Innovation Inc announced that it has made a strategic investment in Solx, Inc., a Massachusetts-based, privately-held medical device company. Principally backed by MVM Life Science Partners, a leading global life science venture capital firm, Solx develops innovative surgical technologies that treat glaucoma and preserve vision.
Spotlight Innovation Inc. identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance.
Solx's lead product is the SOLX Gold Shunt™, a first-in-class, implantable drainage device designed to reduce elevated intraocular pressure (IOP) associated with refractory glaucoma without creating a bleb. The device provides a pathway for the flow of aqueous humor from the anterior chamber to the suprachoroidal space, utilizing a natural pressure differential within the eye. Approved for use in Canada and Europe, the SOLX Gold Shunt has been tested in a multi-center clinical trial, is investigational and awaiting FDA approval in the U.S.
Mr. Kevin McMahon, President and Chief Executive Officer of Solx, commented, "We are very pleased to have Spotlight Innovation join the great team of investors supporting us on our journey. Their involvement validates our belief that the SOLX Gold Shunt will provide glaucoma surgeons with an important new tool for treating patients challenged by severe glaucoma."
About Solx, Inc.
Solx, Inc. is dedicated to developing innovative surgical technologies that treat glaucoma and preserve vision. Privately held, the company is backed by MVM Life Science Partners, River Street Management, Easton Capital, Spotlight Innovation, institutional and other investors. For more information, visit www.solx.com.
About Spotlight Innovation Inc.
Spotlight Innovation Inc identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com .